Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Moodys
Johnson and Johnson
Medtronic
AstraZeneca

Last Updated: November 15, 2019

DrugPatentWatch Database Preview

DOVONEX Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Dovonex, and what generic alternatives are available?

Dovonex is a drug marketed by Leo Pharma As and Leo Pharm and is included in three NDAs.

The generic ingredient in DOVONEX is calcipotriene. There are twelve drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the calcipotriene profile page.

Drug patent expirations by year for DOVONEX
Drug Prices for DOVONEX

See drug prices for DOVONEX

Recent Clinical Trials for DOVONEX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Northwestern UniversityN/A
Washington University School of MedicinePhase 0
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Phase 2/Phase 3

See all DOVONEX clinical trials

Recent Litigation for DOVONEX

Identify potential future generic entrants

District Court Litigation
Case NameDate
LEO Pharma A/S v. Tolmar Inc.2010-08-25
LEO Pharma A/S v. Tolmar Inc.2010-04-06
Bone Care International LLC v. Pentech Pharmaceuticals, Inc.2008-02-21

See all DOVONEX litigation

Pharmacology for DOVONEX
Synonyms for DOVONEX
(1?,3?,5Z,7E,22E,24S)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1,3,24-triol
(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(1R,2E,4S)-4-Cyclopropyl-4-hydroxy-1-methyl-2-buten-1-yl]octahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-1,3-cyclohexanediol
(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
(1S,3R,5Z,7E,14beta,17alpha,22E,24S)-26,27-cyclo-9,10-secocholesta-5,7,10,22-tetraene-1,3,24-triol
(1S,3R,5Z,7E,22E,24S)-26,27-cyclo-9,10-secocholesta-5,7,10,22-tetraene-1,3,24-triol
(1S,5Z,7Z,17ALPHA,22E)-24-CYCLOPROPYL-9,10-SECOCHOLA-5,7,10,22-TETRAENE-1,3,24-TRIOL
(1S,5Z,7Z,17ALPHA,22E)-24-CYCLOPROPYL-9,10-SECOCHOLA-5,7,10,22-TETRAENE-1,3,24-TRIOL; 1-ALPHA,24S-(OH)2-22-ENE-26,27-DEHYDROVITAMIN D3
(22E)-(24S)-1alpha,24-dihydroxy-26,27-cyclo-22,23-didehydrovitamin D3 / (22E)-(24S)-1alpha,24-dihydroxy-26,27-cyclo-22,23-didehydrocholecalciferol / Calcipotriol
(5Z,7E,22E,24S)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1alpha,3beta,24-triol
(5Z,7E,22E,24S)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1alpha,3beta,24-triol hydrate
(5Z,7E,22E)-(1S,3R,24S)-26,27-cyclo-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,24-triol
(5Z,7E,24S)-26,27-Cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1alpha,3beta,24-triol
1-ALPHA,24S-(OH)2-22-ENE-26,27-DEHYDROVITAMIN D3
112828-00-9
112965-21-6
143NQ3779B
147657-22-5
1s19
24207-EP2275420A1
24207-EP2295055A2
24207-EP2295416A2
24207-EP2298748A2
24207-EP2298764A1
24207-EP2298765A1
24207-EP2305640A2
24207-EP2305642A2
24207-EP2308861A1
24207-EP2311453A1
24207-EP2314590A1
828C009
9,10-Secochola-5,7,10(19),22-tetraene-1,3,24-triol, 24-cyclopropyl-, (1alpha,3beta,5Z,7E,22E,24S)-
AB00698343-05
AC1NRC3V
AKOS015855239
BDBM50369964
BMS-181161
calcipotriene
Calcipotriene (USAN)
Calcipotriene [USAN]
CALCIPOTRIENE HYDRATE
Calcipotriol
Calcipotriol (JAN)
Calcipotriol [INN]
Calcipotriol hydrate
Calciptriol
Calciptriol, MC-903, Daivonex, Dovonex, Psorcutan
Calcitrene
CAS-112965-21-6
CCG-100949
CCRIS 7700
CHEBI:50749
CHEMBL1200666
CPD000466353
CS-0387
D01125
Daivonex
DB02300
Divonex
Dovonex (TN)
DSSTox_CID_26648
DSSTox_GSID_46648
DSSTox_RID_81793
DTXSID0046648
Epitope ID:114242
GTPL2778
HMS2051N11
HMS2089J08
HMS3269P03
HMS3713K08
HY-10001
LMST03020106
LWQQLNNNIPYSNX-UROSTWAQSA-N
MC 903
MC-903
MC903
MFCD10567086
MLS000759467
MLS001424130
NC00199
NCGC00167465-01
NCGC00167465-02
O763
PRI 2201
Psorcutan
PubChem18810
PubChem19334
SCHEMBL2853
SMR000466353
Sorilux
SR-01000762910
SR-01000762910-3
SR-01000762910-4
STF-115469
Tox21_112469
Tox21_112469_1
U-0267
UNII-143NQ3779B
W-5148
ZINC3921872
Paragraph IV (Patent) Challenges for DOVONEX
Tradename Dosage Ingredient NDA Submissiondate
DOVONEX CREAM;TOPICAL calcipotriene 020554 2009-12-02
DOVONEX SOLUTION;TOPICAL calcipotriene 020611 2006-05-19

US Patents and Regulatory Information for DOVONEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Leo Pharma As DOVONEX calcipotriene CREAM;TOPICAL 020554-001 Jul 22, 1996 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Leo Pharma As DOVONEX calcipotriene OINTMENT;TOPICAL 020273-001 Dec 29, 1993 DISCN Yes No   Start Trial   Start Trial   Start Trial
Leo Pharm DOVONEX calcipotriene SOLUTION;TOPICAL 020611-001 Mar 3, 1997 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DOVONEX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Leo Pharm DOVONEX calcipotriene SOLUTION;TOPICAL 020611-001 Mar 3, 1997   Start Trial   Start Trial
Leo Pharma As DOVONEX calcipotriene CREAM;TOPICAL 020554-001 Jul 22, 1996   Start Trial   Start Trial
Leo Pharma As DOVONEX calcipotriene OINTMENT;TOPICAL 020273-001 Dec 29, 1993   Start Trial   Start Trial
Leo Pharm DOVONEX calcipotriene SOLUTION;TOPICAL 020611-001 Mar 3, 1997   Start Trial   Start Trial
Leo Pharma As DOVONEX calcipotriene CREAM;TOPICAL 020554-001 Jul 22, 1996   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Moodys
Mallinckrodt
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.